Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CALT
DateTimeSourceHeadlineSymbolCompany
15/05/202422:30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202422:24PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202421:36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
15/05/202421:30PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202421:52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
14/05/202421:35PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202416:16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
06/05/202416:11PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
25/04/202403:35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
25/04/202403:26PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202417:30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
24/04/202417:26PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202421:13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
18/04/202421:10PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202421:24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
09/04/202421:22PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202422:38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202422:32PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202417:24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
08/04/202417:22PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
12/03/202412:28PR Newswire (US)Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®NASDAQ:CALTCalliditas Therapeutics AB
06/03/202418:38PR Newswire (US)Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®NASDAQ:CALTCalliditas Therapeutics AB
06/03/202418:34PR Newswire (US)Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®NASDAQ:CALTCalliditas Therapeutics AB
01/03/202423:43PR Newswire (US)Calliditas Therapeutics to Attend Investor Conferences in MarchNASDAQ:CALTCalliditas Therapeutics AB
01/03/202423:39PR Newswire (US)Calliditas Therapeutics to Attend Investor Conferences in MarchNASDAQ:CALTCalliditas Therapeutics AB
21/02/202417:45PR Newswire (US)Calliditas Year-end report, January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
21/02/202417:43PR Newswire (US)Calliditas Year-end report, January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
14/02/202417:11PR Newswire (US)Invitation to the presentation of Calliditas´ Year-end report January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
14/02/202417:09PR Newswire (US)Invitation to the presentation of Calliditas´ Year-end report January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
14/02/202403:28PR Newswire (US)Calliditas provides patent updateNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT